Bloomberg -- Genmab A/S rose the most in almost two years in Copenhagen trading after an analyst said the biotechnology company is undervalued, making it a takeover target for GlaxoSmithKline Plc.
Bloomberg -- Genmab A/S rose the most in almost two years in Copenhagen trading after an analyst said the biotechnology company is undervalued, making it a takeover target for GlaxoSmithKline Plc.